Mirum Pharmaceuticals nabs $120 mln Series A in NEA-led round

Mirum Pharmaceuticals, a clinical-stage therapeutics company focused on treating cholestatic liver diseases, has secured $120 million in Series A financing. New Enterprise Associates led the round with participation from Deerfield Management, Frazier Healthcare Partners, Novo Holdings A/S, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!